You are here

Yescarta

Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price

Endpoints

Thu, 12/21/17 - 10:12 am

Gilead Sciences

Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup?

Fierce Pharma

Fri, 12/15/17 - 11:35 pm

Gilead Sciences

ASH 2017: CAR-T Wallops Blood Cancer

Motley Fool

Tue, 12/12/17 - 11:16 am

Gilead Sciences

Juno Therapeutics

ASH17: Benefit of Gilead's CAR-T remains durable over longer term

BioPharma Dive

Sun, 12/10/17 - 11:27 pm

Gilead Sciences

diffuse large B-cell lymphoma

Gilead Slaps Mega-Price on Its Newly Approved CAR-T

Motley Fool

Fri, 10/20/17 - 09:04 am

Gilead Sciences

Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod

Fierce Pharma

Thu, 10/19/17 - 09:12 am

Gilead Sciences

non-Hodgkin's lymphoma

large B-cell lymphoma

Pages